SILENCE THERAP. SP.ADR/1 (XRP2) - Total Assets
Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) holds total assets worth €131.44 Million EUR (≈ $153.67 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SILENCE THERAP. SP.ADR/1 - Total Assets Trend (2021–2025)
This chart illustrates how SILENCE THERAP. SP.ADR/1's total assets have evolved over time, based on quarterly financial data. Also see SILENCE THERAP. SP.ADR/1 market capitalisation for the company's overall valuation and market capitalisation.
SILENCE THERAP. SP.ADR/1 - Asset Composition Analysis
Current Asset Composition (December 2025)
SILENCE THERAP. SP.ADR/1's total assets of €131.44 Million consist of 90.3% current assets and 9.7% non-current assets. Review XRP2 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.6% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €288.00K | 0.2% |
| Goodwill | €10.62 Million | 8.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how SILENCE THERAP. SP.ADR/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See XRP2 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SILENCE THERAP. SP.ADR/1's current assets represent 90.3% of total assets in 2025, an increase from 89.8% in 2021.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2025, down from 76.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 7.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 8.1% of total assets.
SILENCE THERAP. SP.ADR/1 Competitors by Total Assets
Key competitors of SILENCE THERAP. SP.ADR/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
SILENCE THERAP. SP.ADR/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.72 | 11.14 | 9.31 |
| Quick Ratio | 8.72 | 11.14 | 9.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €105.05 Million | €170.54 Million | €188.15 Million |
SILENCE THERAP. SP.ADR/1 - Advanced Valuation Insights
This section examines the relationship between SILENCE THERAP. SP.ADR/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.34 |
| Latest Market Cap to Assets Ratio | 1.87 |
| Asset Growth Rate (YoY) | -35.1% |
| Total Assets | €131.44 Million |
| Market Capitalization | $245.62 Million USD |
Valuation Analysis
Above Book Valuation: The market values SILENCE THERAP. SP.ADR/1's assets above their book value (1.87x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: SILENCE THERAP. SP.ADR/1's assets decreased by 35.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual total assets of SILENCE THERAP. SP.ADR/1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €131.44 Million ≈ $153.67 Million |
-35.13% |
| 2024-12-31 | €202.63 Million ≈ $236.90 Million |
+69.64% |
| 2023-12-31 | €119.45 Million ≈ $139.65 Million |
-8.19% |
| 2022-12-31 | €130.10 Million ≈ $152.10 Million |
+0.21% |
| 2021-12-31 | €129.83 Million ≈ $151.78 Million |
-- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more